S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
S&P 500   5,018.03 (+0.14%)
DOW   37,952.09 (+0.47%)
QQQ   421.92 (-0.35%)
AAPL   165.93 (-0.66%)
MSFT   403.98 (-0.07%)
META   497.10 (-0.94%)
GOOGL   155.28 (-0.47%)
AMZN   177.49 (-0.97%)
TSLA   150.32 (+0.26%)
NVDA   841.05 (-0.67%)
AMD   150.98 (-2.64%)
NIO   3.92 (-2.00%)
BABA   68.90 (+0.03%)
T   16.36 (+0.18%)
F   12.12 (+0.50%)
MU   110.35 (-1.41%)
GE   153.02 (+0.05%)
CGC   8.11 (+3.58%)
DIS   112.06 (-0.33%)
AMC   2.89 (-1.03%)
PFE   25.41 (+0.08%)
PYPL   62.35 (+0.40%)
XOM   119.54 (+0.86%)
Free Trial
NASDAQ:PRDS

Pardes Biosciences (PRDS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free PRDS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.16
▼
$2.16
50-Day Range
$2.13
▼
$2.16
52-Week Range
$0.75
▼
$3.93
Volume
400 shs
Average Volume
359,530 shs
Market Capitalization
$133.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
PRDS stock logo

About Pardes Biosciences Stock (NASDAQ:PRDS)

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.

PRDS Stock News Headlines

October 31, 2023 | yahoo.com
Pardes Hanna, Israel - Weather Forecasts | Maps | News - Yahoo Weather
August 31, 2023 | finance.yahoo.com
Pardes Biosciences Announces Closing of Tender Offer
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
August 28, 2023 | finance.yahoo.com
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
August 17, 2023 | finance.yahoo.com
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares
August 3, 2023 | msn.com
Pardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28
July 19, 2023 | marketwatch.com
Pardes Biosciences Shares Rise 15% After Buyout Offer From MediPacific
July 19, 2023 | markets.businessinsider.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)
April 19, 2024 | Altimetry (Ad)
I’m officially sounding the alarm.
AI has been the hottest financial story of 2023. And rightly so – AI stocks have beat the broader market by over 62%. But right now, my system is warning me that many AI stocks are riding higher on hype alone.
July 18, 2023 | msn.com
JMP Securities Downgrades Pardes Biosciences (PRDS)
July 17, 2023 | benzinga.com
PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders
July 17, 2023 | msn.com
Pardes Biosciences stock rallies on buyout offer from MediPacific
July 17, 2023 | benzinga.com
Why Pardes Biosciences Shares Are Rising Monday
July 17, 2023 | markets.businessinsider.com
Pardes Biosciences To Be Acquired By MediPacific; Pardes Up In Pre-market
July 17, 2023 | finance.yahoo.com
Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights
June 5, 2023 | finance.yahoo.com
All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy
May 17, 2023 | seekingalpha.com
Pardes Biosciences Seeking Strategic Alternatives
May 9, 2023 | markets.businessinsider.com
Pardes Biosciences (PRDS) Receives a Hold from SVB Securities
May 6, 2023 | barrons.com
Pardes Biosciences Inc.
May 6, 2023 | finanznachrichten.de
Pardes Biosciences, Inc: Pardes Biosciences Reports First Quarter 2023 Financial Results
May 5, 2023 | msn.com
Recap: Pardes Biosciences Q1 Earnings
May 5, 2023 | finance.yahoo.com
Pardes Biosciences Reports First Quarter 2023 Financial Results
April 12, 2023 | benzinga.com
Analyst Rating: Will Pardes Biosciences Inc (PRDS) Stock Do Better Than the Market?
April 7, 2023 | seekingalpha.com
Pardes Biosciences cut at Jefferies on COVID drug failure
April 4, 2023 | msn.com
SVB Leerink Downgrades FS Development Corp II (PRDS)
April 4, 2023 | markets.businessinsider.com
SVB Securities downgrades Pardes Biosciences (PRDS) to a Hold
April 3, 2023 | msn.com
Pardes slumps ~10% after COVID drug trial failure prompts strategic review
See More Headlines
Receive PRDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PRDS
CUSIP
N/A
CIK
1822711
Web
www.pardesbio.com
Phone
415-649-8758
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-96,630,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-43.36%
Return on Assets
-40.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
81.72
Quick Ratio
81.72

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.51 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
62,012,000
Free Float
36,711,000
Market Cap
$133.95 million
Optionable
Not Optionable
Beta
0.42
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Thomas G. Wiggans (Age 71)
    CEO & Chairman
    Comp: $859.4k
  • Dr. Uri A. Lopatin M.D. (Age 51)
    Founder & Director
    Comp: $786.96k
  • Ms. Heidi Henson CPA (Age 57)
    Chief Financial Officer
    Comp: $564.6k
  • Ms. Elizabeth Haber Lacy J.D. (Age 56)
    Gen. Counsel & Corp. Sec.

Key Competitors

View All Competitors

PRDS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pardes Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pardes Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRDS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRDS, but not buy additional shares or sell existing shares.
View PRDS analyst ratings or view top-rated stocks.

This page (NASDAQ:PRDS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research